Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 2/20 | 0.63 |
| ▸ | TTR | P02766 | 1/20 | 0.63 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.63 |
| ▸ | CDK2 | P24941 | 1/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.63 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.62 |
| ▸ | FABP1 | P07148 | 1/20 | 0.56 |
| ▸ | SNCA | P37840 | 3/20 | 0.46 |
| ▸ | CHAT | P28329 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 5/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4646671 | 0.86 | FABP4 (0.76) | FABP4TTRCCNA2CDK2MAPK14 | |
| SCHEMBL27945094 | 0.84 | CDK2 (0.65) | FABP4TTRCCNA2CDK2MAPK14 | |
| SCHEMBL29381891 | 0.78 | FABP4 (1.00) | FABP4TTRCCNA2CDK2MAPK14 | |
| SCHEMBL43158 | 0.78 | FABP4 (1.00) | FABP4TTRCCNA2CDK2MAPK14 | |
| Ammonia Solution, Strong SCHEMBL592280 | 0.77 | NR4A1 (1.00) | FABP4TTRCCNA2CDK2MAPK14 | |
| SCHEMBL1786500 | 0.77 | FABP4 (0.97) | FABP4TTRCCNA2CDK2MAPK14 | |
| Ammonia Solution, Strong SCHEMBL592279 | 0.77 | NR4A1 (1.00) | FABP4TTRCCNA2CDK2MAPK14 | |
| SCHEMBL6654772 | 0.77 | FABP4 (0.97) | FABP4TTRCCNA2CDK2MAPK14 | |
| SCHEMBL10353163 | 0.77 | FABP4 (0.97) | FABP4TTRCCNA2CDK2MAPK14 | |
| Ammonia Solution, Strong SCHEMBL31666356 | 0.75 | NR4A1 (0.97) | FABP4TTRCCNA2CDK2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583897-B2 | Synthetic foldable proteins generated from peptide segments of folding nuclei of reference proteins | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20230265142-A1 | SYNTHETIC FOLDABLE PROTEINS GENERATED FROM PEPTIDE SEGMENTS OF FOLDING NUCLEI OF REFERENCE PROTEINS | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11479590-B2 | Synthetic foldable proteins generated from peptide segments of folding nuclei of reference proteins | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2022-10-25 | — | — | US | disclosed |
| US-20170362289-A1 | SYNTHETIC FOLDABLE PROTEINS GENERATED FROM PEPTIDE SEGMENTS OF FOLDING NUCLEI OF REFERENCE PROTEINS | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-2547207-A1 | RISPERIDONE IMMUNOASSAY | Saladax Biomedical Inc. (US) | 2013-01-23 | — | — | EP | disclosed |
| EP-2544540-A1 | LENALIDOMIDE AND THALIDOMIDE IMMUNOASSAYS | Saladax Biomedical Inc. (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2012161938-A1 | CLOZAPINE IMMUNOASSAY | SALADAX BIOMEDICAL INC. (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2012161948-A1 | GEMCITABINE IMMUNOASSAY | SALADAX BIOMEDICAL INC. (US) | 2012-11-29 | — | — | WO | disclosed |
| EP-2467139-A1 | IMATINIB IMMUNOASSAY | Saladax Biomedical Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| EP-2467400-A1 | VARIANT IMMUNOGLOBULINS WITH IMPROVED MANUFACTURABILITY | Lonza Biologics plc. (GB) | 2012-06-27 | — | — | EP | disclosed |
| EP-1846763-A2 | 5-FLUORO-URACIL IMMUNOASSAY | Saladax Biomedical Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| EP-1789791-A2 | BUSULFAN IMMUNOASSAY | Saladax Biomedical Inc. (US) | 2007-05-30 | — | — | EP | disclosed |
| EP-1774331-A2 | CYTOXAN ANTIBODIES AND IMMUNOASSAY | Saladax Biomedical Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| EP-1771732-A2 | TAXOL IMMUNOASSAY | Saladax Biomedical Inc. (US) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006104970-A1 | DOXORUBICIN IMMUNOASSAY | SALADAX BIOMEDICAL INC. (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006102200-A2 | DOCETAXEL IMMUNOASSAY | SALADAX BIOMEDICAL INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006086208-A2 | 5-FLUORO-URACIL IMMUNOASSAY | SALADAX BIOMEDICAL INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006031912-A2 | BUSULFAN IMMUNOASSAY | SALADAX BIOMEDICAL INC. (US) | 2006-03-23 | — | — | WO | disclosed |
| WO-2006020263-A2 | CYTOXAN ANTIBODIES AND IMMUNOASSAY | SALADAX BIOMEDICAL INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| WO-2006015098-A2 | TAXOL IMMUNOASSAY | SALADAX BIOMEDICAL INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583897-B2 | Synthetic foldable proteins generated from peptide segments of folding nuclei of reference proteins | MAX, SET, SFPQ | FABP4 1236/4885TTR 1623/4885CCNA2 3042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.